FAS Wealth Partners Inc. Has $395,000 Stake in SPDR S&P Biotech ETF (NYSEARCA:XBI)

FAS Wealth Partners Inc. boosted its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report) by 134.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,429 shares of the exchange traded fund’s stock after acquiring an additional 2,540 shares during the period. FAS Wealth Partners Inc.’s holdings in SPDR S&P Biotech ETF were worth $395,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of XBI. JPMorgan Chase & Co. lifted its position in SPDR S&P Biotech ETF by 179.1% during the 1st quarter. JPMorgan Chase & Co. now owns 7,534,471 shares of the exchange traded fund’s stock worth $574,202,000 after acquiring an additional 4,835,071 shares during the last quarter. Jane Street Group LLC lifted its position in SPDR S&P Biotech ETF by 111.4% during the 2nd quarter. Jane Street Group LLC now owns 172,730 shares of the exchange traded fund’s stock worth $12,829,000 after acquiring an additional 1,682,382 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. acquired a new position in SPDR S&P Biotech ETF during the 3rd quarter worth $102,900,000. Healthcare of Ontario Pension Plan Trust Fund lifted its position in SPDR S&P Biotech ETF by 103.3% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,771,000 shares of the exchange traded fund’s stock worth $129,318,000 after acquiring an additional 900,000 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in SPDR S&P Biotech ETF during the 1st quarter worth $34,666,000.

SPDR S&P Biotech ETF Price Performance

SPDR S&P Biotech ETF stock opened at $90.68 on Wednesday. The firm has a fifty day moving average price of $93.71 and a two-hundred day moving average price of $83.03. The firm has a market cap of $6.96 billion, a price-to-earnings ratio of 11.47 and a beta of 0.97. SPDR S&P Biotech ETF has a fifty-two week low of $63.80 and a fifty-two week high of $103.52.

SPDR S&P Biotech ETF Company Profile

(Free Report)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Read More

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.